ClinicalTrials.Veeva

Menu

WIBOFA - Validation of SCT02 With ECG-App for Detection of AF

Withings logo

Withings

Status

Enrolling

Conditions

Atrial Fibrillation

Treatments

Device: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Device: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording

Study type

Interventional

Funder types

Industry

Identifiers

NCT06351761
SCT02-ECG

Details and patient eligibility

About

The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

Enrollment

371 estimated patients

Sex

All

Ages

22+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or female who are 22 years of age or older
  • Subject able to read, understand, and provide written informed consent
  • Subject willing and able to participate in the study procedures as described in the consent form
  • Subject able to communicate effectively with and willing to follow instructions from the study staff

Exclusion criteria

  • Subject with an implanted electrical device (i.e. pacemaker, ICD ...), whether active or inactive
  • Pathologic disorders that may affect motricity resulting in significant hands tremor that prevents subject from being able to hold still (e.g. Parkinson disease)
  • Myocardial Infarction (MI) within 90 days prior to the enrollment
  • Pulmonary embolism or pulmonary infarction within 90 days prior to the enrollment
  • Stroke or Transient Ischemic Attack (TIA) within 90 days prior to the enrollment
  • Active or history of life-threatening rhythms as determined by investigators (e.g. ventricular tachycardia, ventricular fibrillation, 3rd degree heart block)
  • Any cardiovascular disease that investigators would consider as a risk to subject or renders data uninterpretable (e.g. recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)
  • Active or symptomatic skin disease on Schiller electrode attachment sites or fingertips which would be in contact with BeamO electrodes (e.g. eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis)
  • Known sensitivity to medical adhesives, isopropyl alcohol,, electrocardiogram (ECG) electrodes, including known allergy or sensitivity to stainless steel (used in BeamO electrodes).

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

371 participants in 3 patient groups

Normal Sinus Rhythm
Experimental group
Description:
Simultaneous ECG recording of patient with Normal Sinus Rhythm with investigational and reference devices
Treatment:
Device: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording
Device: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Atrial Fibrillation
Experimental group
Description:
Simultaneous ECG recording of patient with Atrial Fibrillation with investigational and reference devices
Treatment:
Device: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording
Device: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Arrhythmia other than Atrial Fibrillation
Experimental group
Description:
Simultaneous ECG recording of patient with Arrhythmia other than Atrial Fibrillation with investigational and reference devices
Treatment:
Device: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording
Device: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording

Trial contacts and locations

4

Loading...

Central trial contact

Aline Criton

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems